Although it had previously been suggested that the hedgehog (HH) pathway might be activated in some lung tumors, the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. During a screen of a panel of 60 human tumor cell lines with an HH antagonist, we observed that the proliferation of a subset of NSCLC cell lines was inhibited. These NSCLC cell lines express HH, as well as key HH target genes, consistent with them being activated through an autocrine mechanism. Interestingly, we also identified a number of NSCLC cell lines that express high levels of the downstream transcription factor GLI1 and harbor enhanced levels of HH activity, but appear insensitive to known HH antagonists. We hypothesized that the high levels of GLI1 in these cells would function downstream of the HH antagonist target, allowing them to bypass the antagonist-mediated block in proliferation. Consistent with this hypothesis, when the levels of GLI1 are knocked down in such cells, they become sensitive to these inhibitors. We go on to show that a large percentage of primary NSCLC samples express GLI1, consistent with constitutive activation of the HH pathway in these samples. Taken together, these results establish the involvement of the HH signaling pathway in a subset of NSCLCs.
Introduction
The HEDGEHOG (HH) family of secreted proteins, which consists of SONIC (SHH), INDIAN and DESERT HEDGEHOG, play an important role in mammalian development, acting as morphogens, growth factors and survival factors (Ingham and McMahon, 2001; Goetz et al., 2002; Singh et al., 2006) . The HH receptor PATCHED (PTC) functions as an inhibitor of HH signaling. After HH binds to PTC, signaling is activated through derepression of the seven transmembrane protein SMOOTHENED (SMO) (Ogden et al., 2004; Hooper and Scott, 2005) . Ultimately, activated SMO regulates the GLI family of transcription factors by activating GLI1 and GLI2 and inactivating GLI3 (Ingham and McMahon, 2001 ). Increasingly, deregulation of the HH pathway is implicated as an initiating or maintenance factor in the progression of various cancers (Taipale and Beachy, 2001; Ruiz i Altaba et al., 2002; Pasca di Magliano and Hebrok, 2003; Borzillo and Lippa, 2005; Robbins et al., 2005) . Consistent with constitutive HH signaling being an initiating event in cancer, PTC1 loss-of-function mutations behave as tumor suppressors and SMO gainof-function mutations behave as oncogenes (Ruiz i Altaba, 1999; Toftgard, 2000; Bale and Yu, 2001; Taipale and Beachy, 2001 ). In the majority of these cases, PTC1 and SMO mutations were found in tumors derived from patients with medulloblastoma, rhabdomyosarcoma or basal cell carcinoma. Mutations in other components of the HH pathway have also been identified from these types of tumors. Recently, HH itself has been implicated as a survival factor for other tumor types, including cancers of the pancreas Thayer et al., 2003) , prostate (Fan et al., 2004; Karhadkar et al., 2004; Sanchez et al., 2004; Sheng et al., 2004) , breast (Kubo et al., 2004) and small cell lung carcinoma (SCLC) (Watkins et al., 2003) . Cells derived from these tumors require HH for their viability, as the proliferation of these cells is attenuated when they are treated with HH antagonists. In these latter cases, the HH pathway typically functions in an autocrine manner, as HH is produced in the same cells where it acts.
One of the first HH antagonists identified was the plant-derived teratogen called cyclopamine (Cooper et al., 1998; Incardona et al., 1998) . Cyclopamine functions as an HH antagonist by binding and inactivating SMO function (Chen et al., 2002a) . Other small-molecule SMO antagonists were later identified, based on their ability to inhibit a cell-based HHdependent reporter gene assay (Chen et al., 2002b; Williams et al., 2003; Romer et al., 2004) . Some of these inhibitors were used to demonstrate that specific cancers require HH for viability, as these antagonists inhibit the proliferation of these tumor cells in a dose-dependent manner (Williams et al., 2003; Romer et al., 2004) . Independent of these SMO antagonists, an inhibitory monoclonal antibody to SHH also inhibits the growth of HH-dependent tumor cells Thayer et al., 2003; Watkins and Peacock, 2004) . As a further control for the specificity of the SMO antagonists, cells transfected with GLI1, which acts downstream of SMO (Cooper et al., 1998) , bypassed the effects of the SMO antagonist and continued to proliferate. Thus, these SMO antagonists have become useful tools to identify human tumors that are HHdependent.
It has been estimated that 25% of all human tumors require Hedgehog (HH) signaling to maintain tumor cell viability (Lum and Beachy, 2004) . Identification of clinical biomarkers of HH dependence and development of potent HH inhibitors have each become important for treatment of diverse human tumors. One invaluable resource to pursue these goals is available through the Developmental Therapeutics Program (DTP) at the National Cancer Institute (NCI) (Weinstein et al., 1997) . The DTP has screened more than 70 000 compounds for their ability to inhibit the growth of a well-characterized panel of 60 human cancer cell lines (NCI-60). These cancer cell lines include those derived from melanoma, leukemia, lung, central nervous system, kidney, ovary, colon, breast and prostate. At the DTP, the drug concentration resulting in 50% growth inhibition (GI 50 ) is determined for each cell line. The GI 50 of a particular agent administered individually over 60 distinct cell lines gives each small molecule tested a distinct 'fingerprint' signature. This fingerprint can be used to identify other inhibitors screened by the DTP that have a similar fingerprint across the NCI-60 panel. DNA microarray analyses have also been performed on this NCI-60 panel, allowing comparisons of the gene expression profiles of drug-sensitive and -insensitive cell lines.
We submitted the SMO antagonist SANT1 (Chen et al., 2002b) to the DTP for evaluation as an inhibitor of tumor cell proliferation. These analyses showed that a subset of all the examined cell lines tested require HH activity for viability. This data set was validated, focusing on HH in lung cancer because of its substantial impact worldwide on cancer mortality and morbidity. Lung cancers are classified as non-small cell lung carcinoma (NSCLC) and SCLC (Minna et al., 2002) . Approximately 80% of lung cancers are NSCLCs. It has been reported that constitutive HH signaling is frequent in SCLC (Watkins et al., 2003) . Here, we report that the HH pathway is also constitutively active in a subset of NSCLCs. Furthermore, this study suggests that NSCLCs may be classified into three distinct subtypes: those that do not require HH activity, those that require HH activity and are sensitive to known HH inhibitors and those that require HH activity but are insensitive to current HH inhibitors, because they express high levels of GLI1.
Results
At the DTP, different concentrations of a potential therapeutic agent are added to the various cell lines of the NCI-60 panel to determine the GI 50 of that agent for each cell line (Weinstein et al., 1997) . When SANT1 was tested on the NCI-60 panel, the average GI 50 of SANT1 across the panel was 47 mM (data not shown), with a subset of NSCLC cell lines having a GI 50 to SANT1 smaller than one standard deviation (s.d.) of the average GI 50 . As NSCLC is the most common type of lung cancer, and as lung cancer is the most common lethal malignancy for men and women in the US (Landis et al., 1999) , attention was focused on validation of the DTP results in NSCLC cell lines. According to our results from the DTP, the NSCLC cell lines HOP-62 and H322M are most sensitive to inhibition of the HH pathway, whereas A549 and EKVX NSCLC lines are least sensitive to this inhibition (data not shown). Three of these cell lines, two that were sensitive to SANT1, H322M and HOP-62, and one that was insensitive, A549, were initially used to validate this NSCLC data set. Total RNA was isolated from these cell lines and used to verify the expression of key components of the HH signaling pathway, using semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assays. All three cell lines expressed SHH, SMO, PTC1 and GLI1 ( Figure 1a) . As PTC1 and GLI1 are known HH target genes, their expression also serves as a marker of HH pathway activation.
We noted that the SANT1 GI 50 for these NSCLC cell lines was higher than the previously reported SANT1 IC 50 . We assume that this decreased potency is owing to the high HH activity inherent in a cell line that responds to HH in an autocrine manner, as it has been shown that increased exogenous HH protein can overcome cyclopamine's attenuation of the HH pathway (Berman et al., 2002 . Moreover, to demonstrate further that some of these NSCLC cell lines require HH activity for proliferation, proliferation rates of these lines were independently examined with a second SMO antagonist, cyclopamine (Figure 1b) . To control for nonspecific effects on growth inhibition, these cell lines were also treated with tomatidine, a structural analog of cyclopamine incapable of inhibiting the HH pathway (Cooper et al., 1998) . Results were normalized to this control. Consistent with the SANT1 results, cyclopamine inhibited the proliferation of both HOP-62 and H322M cells in a dose-dependent manner. However, cyclopamine had little effect on the growth of A549 cells or on BEAS-2B cells (data not shown), which are an immortalized human lung epithelial cell line. As the IC 50 of cyclopamine for NSCLC cell lines appeared slightly higher than that previously reported for cell lines derived from SCLC and pancreatic tumors, we directly compared the ability of cyclopamine to inhibit the proliferation of an NSCLC cell line and two previously described HH-dependent pancreatic cancer cell lines ( Figure S1 ) . When compared directly, cyclopamine's IC 50 values on either NSCLC or pancreatic tumor cell lines were similar. Therefore, the apparent difference in potency between our study and previous ones is likely due to differences in methodology or to batch-to-batch variations in cyclopamine, which was obtained from a commercial supplier. When taken as a whole, these results show that two structurally distinct SMO antagonists are able to reduce the proliferation of a subset of NSCLC cell lines.
As a control for the specificity of cyclopamine, two cyclopamine-sensitive cell lines were transfected with a plasmid expressing GLI1, then cellular proliferation was measured in the presence of different cyclopamine concentrations (Figure 1c ). Cell lines expressing exogenous GLI1 were less sensitive to cyclopamine than cell lines that expressed a control plasmid. As GLI1 acts downstream of SMO, it can bypass inhibitory effects of an SMO antagonist such as cyclopamine. Still, this experiment underestimates GLI1's ability to overcome the growth-inhibitory effects of cyclopamine, as only about 50% of the cells were transfected. Thus, at most, only 50% of transfectants were able to bypass cyclopamine-induced growth inhibition. To further verify that the ability of cyclopamine to inhibit the growth of NSCLC cells is through inhibition of HH signaling, we determined the ability of cyclopamine to inhibit the expression of the HH target gene PTC1, under conditions in which cell growth was also inhibited (Figure 1d ). RNA was harvested from HOP-62 cells treated with tomatidine or cyclopamine, normalized to vehicle control, then used for quantitative real time RT-PCR analyses. Cyclopamine was able to reduce PTC1 expression in HOP-62 cells, whereas tomatidine had little effect on PTC1 expression in these cells ( Figure 1d ). Thus, cyclopamine's effects on the expression of this HH target gene correlates closely with its ability to inhibit proliferation of the NSCLC cell lines. Together, these results substantiate our results showing that some NSCLC cells require active HH signaling for their proliferation.
Surprisingly, the cyclopamine-insensitive line A549 expressed a similar repertoire of HH components as the cyclopamine-sensitive lines (see Figure 1a) . Furthermore, A549 cells expressed the HH target gene GLI1 to a higher level than NSCLC cell lines that were sensitive to cyclopamine. These results suggested that A549 cells harbor a constitutively active HH signaling pathway, which for some as yet unknown reason was insensitive Hedgehog signaling in lung cancer Z Yuan et al to SMO antagonists. It has been suggested that some prostate cancer cell lines display hyper-activated HH signaling, and that this confers an aggressive growth property that is less sensitive to an HH pathway antagonist . We hypothesized that such NSCLC tumor cell lines also exist. To test this hypothesis, NSCLC cell lines were transfected with an HH reporter gene, in which eight GLI DNA binding sites drive luciferase expression (Figure 2a) , or a control reporter gene. A549 cells contained much higher levels of HH activity than the cell lines expressing less GLI1. Thus, A549 cells exhibit a hyper-activated HH signaling pathway, perhaps explaining their relative insensitivity to cyclopamine. The DNA microarray analyses performed on the various cell lines of the NCI-60 panel, which can be accessed at the DTP website (http:// dtp.nci.nih.gov/), were evaluated to examine relative GLI1 expression levels across the NCI-60 panel. This analysis demonstrates that GLI1 expression only varies two-to fivefold across the majority of these cell lines tested ( Figure 2b ). However, three of these cell lines, all of which were derived from NSCLCs, expressed appreciably higher levels of GLI1 than the other cancer cell lines. A549 cells were one of these three, consistent with the high GLI1 expression observed by RT-PCR assays (see Figure 1a) ; H522 and H23 were the other two cell lines. To verify the overexpression of GLI1 observed in the DTP microarray gene expression database, an expanded panel of NSCLC cell lines, including the three high GLI1 (High-GLI1)-expressing cell lines, were examined for GLI1 expression by immunoblotting ( Figure 2c ). From these analyses, H522, H23 and A549 cells were found to express appreciably higher levels of GLI1 than the other examined NSCLC cell lines. This result is consistent with the DNA microarray analysis of GLI1 expression and the high levels of GLI activity found in A549 cells. According to the DTP results with SANT1, the proliferation of the three High-GLI cell lines, A549, H23 and H522, was less sensitive to SANT1 than HOP-62 and H322M cells. To confirm this observation, proliferation profiles of these cell lines were assessed in the presence of varying amounts of cyclopamine (Figure 3a) . Consistent with the DTP findings, the three High-GLI cell lines were relatively insensitive to cyclopamine, as compared with HOP-62 and H322M cells. As high levels of GLI1 appear to render a cell relatively insensitive to SMO antagonists, we hypothesized that reducing GLI1 expression in a High-GLI cyclopamine-insensitive cell line would increase its sensitivity to such antagonists. To test this hypothesis, the proliferation of A549 cells was monitored after GLI1 expression was reduced using small interfering RNA (siRNA) transfections. The Lysates from the indicated cell lines were subjected to immunoblot analyses using GLI1 or a-TUBLIN antibodies.
Hedgehog signaling in lung cancer Z Yuan et al reduced GLI1 levels approximately 70% compared with a control random siRNA (Figure 3b ). A549 cells treated with the GLI1 targeting siRNA growth arrested when treated with cyclopamine, whereas A549 cells treated with a control siRNA remained relatively cyclopamine insensitive (Figure 3c ). It has been suggested that hyper-activation of the HH signaling pathway is associated with increased tumorigenicity. One measure of such activity is the increased ability of a cell line to grow in an anchorageindependent manner. To directly test this possibility, we determined the ability of HOP-62, a low GLI1-expressing cell line, to form colonies in a soft agar assay in the presence or absence of transfected GLI1 (Figure 3d ). HOP-62 cells expressing exogenous GLI1 had an approximately 100% increase in the number of soft agar colonies formed, compared with cells transfected with a control plasmid. A similar increase was found in the ability of HOP-62 cells expressing exogenous GLI1 to invade across a matrigel layer, which is another measure of increased tumorigenicity (data not shown). Based on these results, it is anticipated that NSCLC cell lines may appear insensitive to SMO antagonists because they contain a hyper-activated HH signaling pathway, which is activated downstream of SMO. Thus, the prevalence of HH-dependent NSCLC cell lines is higher than that predicted from our initial NCI-60 screen. When the three High-GLI cell lines are included as HH-dependent cell lines, the majority of NSCLC cell lines examined require HH activity for proliferation. Moreover, these high GLI1-expressing cell lines may have been derived from more aggressive NSCLCs, although we cannot rule out that such cell lines have been selected for during long-term growth in vitro.
Although the use of cancer cell lines represents an initial step in establishing the impact of HH signaling in NSCLC, ultimately these findings must be confirmed and extended to primary human lung cancer. For this reason, the expression profile of HH signaling components was examined in de novo NSCLCs and this profile was compared with that in adjacent normal lung tissues, as described previously (Albanell et al., 1997; Rusch et al., 1997; Petty et al., 2003 Petty et al., , 2004 Pitha-Rowe et al., 2004) . The majority of primary NSCLC samples examined exhibit increased expression of HH signaling components, including two known HH target genes, as compared with their normal matched lung tissue samples (Figure 4a ). The increased expression of HH signaling components in resected NSCLC samples occurred in all three of the major NSCLC subtypes (Minna et al., 2002) , as depicted in these figures. To validate our RT-PCR analyses of total RNA isolated from resected NSCLCs, GLI1 protein expression was Hedgehog signaling in lung cancer Z Yuan et al also examined in four of the same paired lung cancer/ normal lung specimens by immunoblot analysis (Figure 4b ). Cases 2, 4 and 5 expressed more GLI1 in the tumor as compared with its matched normal lung tissue control, whereas Case 1 expressed similar levels of GLI1 in these matched samples. In general, a correlation was observed between the levels of GLI1 protein and mRNA. However, Case 4 did not appear to follow this correlation, as GLI1 protein levels were higher in the tumor than normal tissue, whereas GLI1 mRNA expression was similar in both samples. We do not yet know the reason for this, perhaps some NSCLCs regulate GLI1 protein levels by a non-transcriptionaldependent mechanism, as has been described previously in basal cell carcinomas (Huntzicker et al., 2006) . To verify that the increased HH activity found in NSCLC samples originated within the tumor cells, we used immunohistochemistry to detect the presence of nuclear GLI1, as a marker of pathway activation, within the NSCLC. Ten pairs of NSCLC and patient-matched non-neoplastic adjacent lung tissues were used in these analyses, the results of which are summarized in Supplementary Table S1 . The majority of these tumors showed intense nuclear GLI1 staining, consistent with an actived HH signaling pathway (Figure 4c ). The majority of the non-neoplastic adjacent tissue did not stain positively for GLI1 (Figure 4d ). However, we also obtained some GLI1 nuclear staining within airway epithelial cells, which may represent the source of GLI1 detected by RT-PCR and immunoblotting in the matched normal controls (Figure 4a and b) . To extend our analyses of HH activation to a greater number of NSCLC cases, we determined the expression of GLI1 across a lung tumor tissue array that contained 120 tissue samples ( Figure 5 ). These results show that the majority of lung adenocarcinoma and squamous cell carcinoma exhibit elevated expression of the HH target gene GLI1. As a control for the specificity of this GLI1 staining, immunostaining of an NSCLC sample was also performed in the presence of an excess of the GLI1 peptide antigen to which the antibody was raised. The presence of excess GLI1 peptide during the immunostaining procedure substantially diminished the GLI1 nuclear staining (Figure S2 ), confirming the specificity of the GLI1 antibody used here. These analyses of primary resected NSCLC cases support our results with NSCLC cell lines, implicating a role for HH signaling in the proliferation of a subset of NSCLCs.
Discussion
The findings presented here demonstrate that HH signaling may play an important growth-regulatory role for a subset of NSCLCs. Two structurally distinct SMO antagonists were used to demonstrate that certain NSCLC cell lines require constitutive HH activity for maintenance of their growth. Furthermore, a close association was established between cyclopaminemediated inhibition of cellular proliferation and attenuation of HH activity, consistent with cyclopamine acting directly on NSCLC cells via inhibition of HH signaling. NSCLC cells overexpressing GLI1 can overcome the growth-inhibitory effects of cyclopamine, independently confirming the specificity of effects signaled by cyclopamine. The majority of NSCLC cell lines examined contained a constitutively active HH signaling pathway; these results were confirmed and extended in paired normal lung-NSCLC specimens and in a lung tumor tissue array. A similar proportion of primary NSCLC samples exhibit a gene expression signature consistent with them harboring a constitutively active HH signaling pathway.
The role of the HH pathway in NSCLC had previously been examined in both cell lines and in primary tumor samples (Watkins et al., 2003) . Although that report shows some evidence for persistent activation of the HH pathway in NSCLC primary samples, the percent of NSCLC in which the HH pathway appeared activated was significantly lower than that Hedgehog signaling in lung cancer Z Yuan et al reported here. Furthermore, in the latter report, no NSCLC cell lines were identified that appeared to exhibit an activated HH pathway, via either increased expression of known HH target genes or by sensitivity to SMO antagonists. Although the reasons for these differences are not yet known, we note that in our study different GLI1 antibodies were used, and speculate that the antibodies used in our study may be more sensitive than those used previously. Similar to the previous work, we also found that the majority of the NSCLC cell lines we examined were relatively SMO antagonist resistant, becoming sensitive to these antagonists only after GLI1 expression was reduced. Regardless of these differences, when taken together, these results suggest that the HH pathway is activated in a subset of primary NSCLC, but that this HH dependence is not commonly found in cell lines derived from these tumors. Consistent with this latter suggestion, the HH signaling pathway appears to be more frequently activated in primary cases of medulloblastoma and SCLC than in cell lines derived from those tumors (Huntzicker et al., 2006; Sasai et al., 2006) . Two subtypes of HH-dependent NSCLC cell lines were uncovered, those expressing low levels of GLI1 (HOP62 and H322M) and those expressing high levels of GLI1 (A549, H522 and H23). The High-GLI lines contain a hyper-activated HH signaling pathway, and are relatively resistant to SMO antagonists. Hyperactivation of HH signaling correlates with increased growth potential of the tumor cell line or metastatic state of the tumor in vivo . GLI1 transfection into prostate cancer cell lines expressing low levels of HH activity resulted in hyper-activation of HH signaling and increased metastatic potential. Furthermore, metastatic prostate cancers expressed higher levels of the HH target genes GLI1 and PTC1 than did localized prostate tumors. These results are in accord with the view that hyper-activated levels of GLI activity, as observed here in NSCLC cells, result from increased GLI1 levels, and with the possibility that these cancer cell lines are derived from clinically aggressive tumors. In this regard, although a number of tumor cell lines derived from different tissues require HH activity for proliferation, only NSCLC cell lines exhibited substantially higher GLI1 basal levels. We speculate that this hyper-activation of HH signaling through increased GLI1 expression may be prevalent in clinical NSCLCs.
Given the diversity of HH-dependent cancers, constitutive HH signaling likely confers a growth advantage to these tumors. It has been proposed that HHdependent tumors may derive at least partly from cancer progenitor cells (CPC) . Consistent with this view, many HH-dependent tumor cells express markers also found in CPC, such as nestin and CD34. These CPC help drive growth of the resultant cancers. Thus, any therapy that does not target these CPC would likely fail, even if the primary cancer responds to therapy, as CPC would rapidly repopulate the residual tumors (Dean et al., 2005) . Recently, lung progenitor cells capable of repopulating different epithelial cells have been reported (Kim et al., 2005) . This population of cells was markedly expanded in the presence of the RAS oncogene, suggesting that these lung progenitor cells are CPC precursors, which give rise to different forms of lung cancer. The findings presented here are consistent with this view, as evidence 
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Z Yuan et al is provided for an important link that involves activation of the HH pathway in the common types of NSCLC. Lung cancer is the leading cause of cancer mortality, for men and women, in the US, with more than 150 000 deaths annually, and overall 5-year survival of only 14% (Landis et al., 1999) . It has been previously estimated that the HH signaling pathway is activated in many SCLCs (Watkins et al., 2003) . Based on the findings presented here, a subset of the more common form of lung cancer, NSCLC, also harbors a constitutively active HH signaling pathway. Thus, bringing HH inhibitors to the clinic could conceivably have a positive therapeutic impact on the treatment, or chemoprevention, in both SCLC and NSCLC.
Material and methods

Cell lines and tissues
The cell lines tested at the DTP, in the order displayed in Figure 2b , are CCRF-CEM, HL-60, K-562, MOLT-4, RPMI-8226, SR, A549, EKVX, HOP-62, HOP-92, H226, H23, H322M, H460, H522, COLO 205, HCC-2998, HCT-116, HCT-15, HT29, KM12, SW-620, SF-268, SF-295, SF-539, SNB-19, SNB-75 , U251, LOX IMVI, MALME-3M, M14, SK-MEL-2, SK-MEL-28, SK-MEL-5, UACC-257, UACC-62, IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, SK-OV-3, 786-0, ACHN, A498, CAKI-1, RXF 393, SN12C, TK-10, UO-31, PC-3, DU-145, MCF7, ADR-RES, MB-231, HS 578T, MB-435, BT-549 and T-47D. HOP-62, H322M, A549, H23, H522 and EKVX were purchased from the DTP, and cultured in a humidified incubator with 5% CO 2 in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS), supplemented with penicillin and streptomycin, as described previously (Robbins et al., 1997) .
Total RNA and protein were isolated from paired normal and malignant lung tissue specimens, as described previously (Albanell et al., 1997; Rusch et al., 1997; Petty et al., 2003 Petty et al., , 2004 Pitha-Rowe et al., 2004) . These tissues were obtained through an Institutional Review Board-approved protocol. No patient identifying information was associated with these specimens.
Assays
The examined cell lines were plated onto a 96-well plate the day before drug treatment. Varying concentrations of cyclopamine (Toronto Research Chemicals, Ontario, Canada), tomatidine (Sigma, St Louis, MO, USA) or vehicle (ethanol) were added to cells in the described medium containing 0.5% FBS, for 2 or 3 days, as indicated in specific experiments. Cell proliferation was determined using the CellTiter-Glo assay (Promega, Madison, WI, USA). In each experiment, every treatment group was replicated in six independent wells. Each experiment was repeated three times, and the average number and s.d. from these experiments were plotted in the displayed figures. The SANT1 used in the DTP screen was purchased from Toronto Research Chemicals (Calbiochem, La Jolla, CA, USA).
HH reporter assays were performed using the GLIBS-Luc reporter construct or TK-luciferase control plasmid (gift from Dr M Hebrok, UCSF, San Francisco, CA, USA) (Thayer et al., 2003) . Cells were transfected with these plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer's specifications. A renilla-expressing construct (RL-TK) was co-transfected as a control for transfection efficiency. Luciferase activity was measured 24 h after transfection, using the Dual Luciferase kit (Promega, Madison, WI, USA).
In the GLI1 overexpression experiment, the GLI1 expression vector SRaGLI1 (gift from Dr S Ishii, Laboratory of Molecular Genetics, RIKEN Tsukuba Institute, Ibaraki, Japan) (Dai et al., 1999) was transfected into HOP-62 or H322M cells using Lipofectamine 2000, followed by cyclopamine treatment 30 h later. Proliferation of the various transfected cells was determined 48 h later. Double-stranded siRNAs were synthesized (Dahrmacon, Lafayette, CO, USA) and transiently transfected into desired cells 30 h before addition of cyclopamine and then assayed for effects on proliferation 48 h later. The siRNA was transfected into cells with TransIT-TKO reagent (Mirus, Madison, WI, USA). The sequences of the GLI1 siRNA and control siRNA were as described previously (Sanchez et al., 2004) .
The RNeasy Protect Mini kit (Qiagen, Valencia, CA, USA) was used to isolate total cellular RNA. The complementary DNA was synthesized using oligo-dT primer and Superscript II reverse transcriptase (Invitrogen). PCR amplifications were performed using Taq polymerase (Invitrogen). The expression of b-Actin or GLYCERALDEHYDE 3-PHOSPHATE DE-HYDROGENASE (GAPDH) was used as a control. The primers (Invitrogen) used were as follows: SMO, forward primer, 5 0 -CAACCTGTTTGCCATGTTTGGA-3 0 , reverse primer 5 0 -CTGTGTCCATCAGGTTGGTG-3 0 ; b-Actin, forward primer, 5 0 -GTCTTCCCCTCCATCGTG-3 0 , reverse primer 5 0 -CCATCTCTTGCTCGAAGTCC-3 0 ; GAPDH, forward primer, 5 0 -ACGTGTCAGTGGTGGACCT-3 0 , and reverse primer, 5 0 -GTCCACCACCCTGTTGCTG-3 0 . The primers for GLI1, SHH and PTC1 were synthesized using published sequences (Zhu et al., 2004) . All the primers were designed to cross an intron-exon boundary, to ensure that the PCR products were not derived from contaminating genomic DNA. Assays were assessed at various PCR cycle numbers to ensure that the PCR products were obtained, whereas the PCR assays were in a linear range. Quantitative real-time PCR was preformed using a FAST 7500 Applied Biosystems ((ABI), Foster city, CA, USA) real-time PCR system with PTC1 and GAPDH inventoried TaqMan gene expression assay probes (ABI). Reactions were performed in triplicate a minimum of three times. Relative quantitation values were determined using the 7500 FAST system software (ABI). PTC1 expression was normalized to GAPDH expression. Cyclopamine-and tomatidine-treated samples were normalized to vehicle control.
Soft agar assays were performed essentially as described previously (Taipale et al., 2000) . Cells were plated in six-well dishes in agar containing 2% FBS. Ten thousand cells were plated in each well, and each treatment had triplicate wells. Fourteen days after plating, colonies were counted in five random fields for each well.
Immunoblot analyses
Lysates were prepared in sodium dodecyl sulfate (SDS) sample buffer (for cell lysates) or Tri Reagent (Molecular Research Center, Cincinnati, OH, USA) (for tumor lysates). Protein concentrations were determined using a BCA Protein Assay (Pierce, Rockford. IL, USA). Equal amounts of total protein were resolved by SDS-polyacrylamide gel electrophoresis and then transferred to nitrocellulose and immunoblotted, as described previously (Robbins et al., 1997) . The antibodies used were as follows: rabbit polyclonal GLI1 (Abcam, Cambridge, MA, USA) and mouse monoclonal a-TUBLIN (Oncogene Research Products, San Diego, CA, USA). The appropriate horseradish peroxidase-conjugated secondary antibodies were used and the signal developed with enhanced chemiluminescence Plus (Amersham Biosciences, UK) or Supersignal West Femto (Pierce).
Immunohistochemistry NSCLC was selected from resection specimens along with patient-matched samples of non-neoplastic lung tissue. Slides were prepared from paraffin-embedded formalin-fixed tissue samples. They were cut in 5 mm-thick sections, heated and then de-paraffinized with xylene. The tissue was re-hydrated with serial dilutions of ethanol. Antigen retrieval was performed in a pressure cooker for 40 min at a maximum of 19 PSI and 1271C, using a citrate buffer (Biogenex, San Ramos, CA, USA). Endogenous peroxidase was then quenched with a 3% solution of hydrogen peroxide. Buffered casein solution was used as a nonspecific blocking agent. The tissue was incubated with 1:100 dilution of rabbit polyclonal anti-GLI1 antibody (Abcam) for 30 min. Primary antibody was detected using the peroxidase-conjugated streptavidin method, and the dimethylbenzadene substrate chromagen (Biogenex), with a light hematoxylin counterstain (Pitha-Rowe et al., 2004) . The tissue was then dehydrated with serial ethanol solutions and finally xylene. In the control experiment for the specificity of the GLI1 immunostaining, GLI1 antibody was incubated with 20 Â GLI1 antigen peptide overnight before being added to the tissue. A basal cell carcinoma of skin was used as a positive control and a representative negative control slide incubated with phosphate-buffered saline was included in the assay. The controls stained appropriately.
Human lung tumor microarray slides were purchased from Asterand (Detroit, MI, USA). Slides were prepared from paraffin-embedded formalin-fixed tissue samples. Samples are represented in triplicate. There are total 120 cases (360 tissue cores) on each slide. Every case has histopathological information available.
